A Long-term Follow-up Study in Participants Who Received CS-101

Enrolling by invitation

Conditions studied: Beta-Thalassemia

In brief

This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-06 (NCT06024876),No investigational drug product will be administered in the study.

Key facts

Study ID

NCT06685536

Run by

CorrectSequence Therapeutics Co., Ltd

People needed

5

Starts

2025-01-18

Expected to finish

2039-07-01

Last updated by the study team

2026-02-10

Who can join

Age: 6 and older, up to 35. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants (or his or her legally appointed and authorized representative or guardian) must sign and date informed consent form (ICF) and, where applicable, an assent form
• Participants must have received CS-101 infusion in last study

You may not qualify if…

• There are no exclusion criteria

Where it is running

• The First Affiliated Hospital of Guangxi Medical University — Nanning, Guangxi, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.